JJ
FATE icon

Johnson & Johnson’s Fate Therapeutics FATE Stock Holding History

Johnson & Johnson’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.12M Hold
3,379,064
– – 1.14% 10
2026
Q1 		$4.05M Hold
3,379,064
– – 0.62% 10
2025
Q4 		$3.32M Hold
3,379,064
– – 0.6% 10
2025
Q3 		$4.26M Hold
3,379,064
– – 0.84% 11
2025
Q2 		$3.51M Hold
3,379,064
– – 1.05% 11
2025
Q1 		$2.67M Hold
3,379,064
– – 0.78% 11
2024
Q4 		$5.58M Hold
3,379,064
– – 1.44% 11
2024
Q3 		$11.8M Hold
3,379,064
– – 2.77% 11
2024
Q2 		$11.1M Hold
3,379,064
– – 2.77% 11
2024
Q1 		$24.8M Hold
3,379,064
– – 0.56% 10
2023
Q4 		$12.6M Hold
3,379,064
– – 0.29% 12
2023
Q3 		$7.16M Hold
3,379,064
– – 2.64% 10
2023
Q2 		$16.1M Hold
3,379,064
– – 4.99% 7
2023
Q1 		$19.3M Hold
3,379,064
– – 6.27% 6
2022
Q4 		$34.1M Hold
3,379,064
– – 9.92% 4
2022
Q3 		$75.7M Hold
3,379,064
– – 22.28% 1
2022
Q2 		$83.7M Hold
3,379,064
– – 21.39% 2
2022
Q1 		$131M Hold
3,379,064
– – 24.77% 1
2021
Q4 		$198M Hold
3,379,064
– – 22.51% 2
2021
Q3 		$200M Buy
+3,379,064
New +$265M 17.57% 3

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Johnson & Johnson's FATE Position: Q2 2026 in Review

Johnson & Johnson held its Fate Therapeutics (FATE) position steady in Q2 2026 at 3,379,064 shares worth $9.12M. The position accounts for 1.14% of the portfolio, ranked #10.

Johnson & Johnson first reported a position in FATE in Q3 2021 and has held it in 20 quarters since. The position peaked at $200M in Q3 2021. 155 funds tracked by Wall St. Rank hold FATE as of Q2 2026.

  • Johnson & Johnson held 3,379,064 shares of Fate Therapeutics worth $9.12M as of Q2 2026.
  • Johnson & Johnson left its Fate Therapeutics share count unchanged in Q2 2026.
  • Fate Therapeutics made up 1.14% of Johnson & Johnson's portfolio in Q2 2026, its #10 holding.
  • Johnson & Johnson first reported a position in Fate Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • Johnson & Johnson's Fate Therapeutics position peaked at $200M in Q3 2021.
  • 155 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2026.

Based on Johnson & Johnson's 13F filing for Q2 2026, filed 6 Aug 2026.